Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration

Abida, Wassim; Patnaik, Akash; Campbell, David; Shapiro, Jeremy; H. Bryce, Alan; McDermott, Ray; Sautois, Brieuc; J. Vogelzang, Nicholas; Bambury, Richard; Voog, Éric; Zhang, Jingsong; M. Piulats, Josep; J. Ryan, Charles; S. Merseburger, Axel; Daugaard, Gedske; Heidenreich, Axel; Fizazi, Karim; S. Higano, Celestia; E. Krieger, Laurence; N. Sternberg, Cora; P. Watkins, Simon; Despain, Darrin; D. Simmons, Andrew; Loehr, Andrea; Dowson, Melanie; Golsorkhi, Tony; Chowdhury, Simon; behalf of the TRITON2 investigators, on

doi:10.1200/jco.20.01035

Public

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene Alteration

Published in Journal of Clinical Oncology • Aug 14, 2020

Authors:

Wassim Abida

Akash Patnaik

David Campbell

Abstract

PURPOSE BRCA1 or BRCA2 ( BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg ...

Subject

Medicine

Prostate cancer

Oncology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!